Published in Am J Psychiatry on September 01, 2002
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) (2003) 2.28
Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov (2008) 2.05
The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences. Schizophr Bull (2007) 1.38
Pharmacological treatment effects on eye movement control. Brain Cogn (2008) 1.30
The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) (2003) 1.29
Motor deficits in schizophrenia quantified by nonlinear analysis of postural sway. PLoS One (2012) 0.89
Phencyclidine/schizophrenia: one view toward the past, the other to the future. Schizophr Bull (2012) 0.85
Alcohol impairment of saccadic and smooth pursuit eye movements: impact of risk factors for alcohol dependence. Psychopharmacology (Berl) (2010) 0.81
The effects of ketamine and risperidone on eye movement control in healthy volunteers. Transl Psychiatry (2013) 0.81
NOS1AP protein levels are altered in BA46 and cerebellum of patients with schizophrenia. Schizophr Res (2010) 0.79
Is persistent ketamine use a valid model of the cognitive and oculomotor deficits in schizophrenia? Biol Psychiatry (2008) 0.78
Neurological soft signs in schizophrenia - The past, the present and the future. Indian J Psychiatry (2012) 0.77
A subanesthetic dose of ketamine in the Rhesus monkey reduces the occurrence of anticipatory saccades. Psychopharmacology (Berl) (2015) 0.75
Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell (2007) 8.99
DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat Neurosci (2010) 3.47
Human postmortem tissue: what quality markers matter? Brain Res (2006) 2.92
Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J Neurosci (2010) 2.84
Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 2.82
The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry (2013) 2.39
Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry (2013) 2.37
Differences in resting-state functional magnetic resonance imaging functional network connectivity between schizophrenia and psychotic bipolar probands and their unaffected first-degree relatives. Biol Psychiatry (2012) 2.33
Conflict of interest. Am J Psychiatry (2006) 2.30
Deficits in syntaxin 1 phosphorylation in schizophrenia prefrontal cortex. Biol Psychiatry (2009) 2.25
Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov (2008) 2.05
Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits. Arch Gen Psychiatry (2009) 2.03
A role for repressive histone methylation in cocaine-induced vulnerability to stress. Neuron (2011) 1.92
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry (2013) 1.85
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78
Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry (2013) 1.76
A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc Natl Acad Sci U S A (2010) 1.70
Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat Med (2013) 1.70
Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res (2004) 1.65
Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. Am J Psychiatry (2012) 1.61
AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol Psychiatry (2008) 1.60
Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia. Neuropsychopharmacology (2006) 1.53
Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry (2013) 1.43
Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology (2009) 1.41
Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia. Am J Psychiatry (2015) 1.40
Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. Am J Psychiatry (2013) 1.35
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry (2010) 1.33
Is aberrant functional connectivity a psychosis endophenotype? A resting state functional magnetic resonance imaging study. Biol Psychiatry (2013) 1.31
Induction of activating transcription factors (ATFs) ATF2, ATF3, and ATF4 in the nucleus accumbens and their regulation of emotional behavior. J Neurosci (2008) 1.27
Genetics and intermediate phenotypes of the schizophrenia--bipolar disorder boundary. Neurosci Biobehav Rev (2009) 1.26
Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry (2011) 1.22
Reimagining psychoses: an agnostic approach to diagnosis. Schizophr Res (2013) 1.20
Serum response factor promotes resilience to chronic social stress through the induction of DeltaFosB. J Neurosci (2010) 1.19
Insight and frontal cortical function in schizophrenia: a review. Schizophr Res (2006) 1.18
Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2003) 1.18
Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry (2002) 1.17
Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry (2005) 1.17
Regional alterations in RGS4 protein in schizophrenia. Synapse (2006) 1.15
Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. Biol Psychiatry (2003) 1.11
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol (2003) 1.10
Long-term psychiatric outcomes following traumatic brain injury: a review of the literature. J Head Trauma Rehabil (2009) 1.10
Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology (2005) 1.08
Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiatry (2003) 1.07
Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry (2012) 1.07
Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol Psychiatry (2007) 1.06
Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacology (2009) 1.06
Specific motion processing pathway deficit during eye tracking in schizophrenia: a performance-matched functional magnetic resonance imaging study. Biol Psychiatry (2005) 1.04
Gamma/beta oscillation and sensory gating deficit in schizophrenia. Neuroreport (2004) 1.04
Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder. Schizophr Bull (2008) 1.03
Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) (2004) 1.03
[(3)H]cAMP binding sites and protein kinase a activity in the prefrontal cortex of suicide victims. Am J Psychiatry (2002) 1.03
Neural activations during auditory oddball processing discriminating schizophrenia and psychotic bipolar disorder. Biol Psychiatry (2012) 1.02
Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia. Neuropsychopharmacology (2012) 1.02
Independent domains of inhibitory gating in schizophrenia and the effect of stimulus interval. Am J Psychiatry (2007) 1.02
Regional expression of RGS4 mRNA in human brain. Eur J Neurosci (2004) 1.01
Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex. Neuropsychopharmacology (2004) 1.01
Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord (2007) 1.00
Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol Psychiatry (2004) 0.99
The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology (Berl) (2005) 0.99
Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology (2003) 0.99
Components of the smooth pursuit function in deficit and nondeficit schizophrenia. Schizophr Res (2003) 0.99
Beta (~16 Hz) frequency neural oscillations mediate auditory sensory gating in humans. Psychophysiology (2007) 0.99
Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia. Neuropsychopharmacology (2005) 0.98
Phosphorylation of the tubulin-binding protein, stathmin, by Cdk5 and MAP kinases in the brain. J Neurochem (2006) 0.98
Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action? Am J Psychiatry (2009) 0.98
Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients. Arch Gen Psychiatry (2006) 0.98
Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull (2006) 0.97
A shared low-frequency oscillatory rhythm abnormality in resting and sensory gating in schizophrenia. Clin Neurophysiol (2011) 0.97
Spatiotemporal and frequency domain analysis of auditory paired stimuli processing in schizophrenia and bipolar disorder with psychosis. Psychophysiology (2011) 0.96
Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia. Psychiatry Res (2005) 0.94
The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry (2002) 0.94
Regulator of G protein signaling 4 [corrected] is a crucial modulator of antidepressant drug action in depression and neuropathic pain models. Proc Natl Acad Sci U S A (2013) 0.94
Hippocampal function, declarative memory, and schizophrenia: anatomic and functional neuroimaging considerations. Curr Neurol Neurosci Rep (2005) 0.94
Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction. Schizophr Bull (2013) 0.94
mRNA and protein expression of selective alpha subunits of G proteins are abnormal in prefrontal cortex of suicide victims. Neuropsychopharmacology (2002) 0.93
Refining the predictive pursuit endophenotype in schizophrenia. Biol Psychiatry (2007) 0.93
Is motion perception deficit in schizophrenia a consequence of eye-tracking abnormality? Biol Psychiatry (2008) 0.91
Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacology (2007) 0.91
Magnetic transfer contrast accurately localizes substantia nigra confirmed by histology. Biol Psychiatry (2012) 0.90
Neurobiological underpinnings of insight deficits in schizophrenia. Int Rev Psychiatry (2007) 0.90
Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2009) 0.90
Memory generalization is selectively altered in the psychosis dimension. Schizophr Res (2012) 0.90
Pathological gambling: focusing on the addiction, not the activity. Am J Psychiatry (2006) 0.90
Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull (2009) 0.89
Role of anticipation in schizophrenia-related pursuit initiation deficits. J Neurophysiol (2005) 0.89
Antipsychotic Drugs Alter Functional Connectivity between the Medial Frontal Cortex, Hippocampus, and Nucleus Accumbens as Measured by H215O PET. Front Psychiatry (2012) 0.89